|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wick W and Platten M: Understanding and
treating glioblastoma. Neurol Clin. 36:485–499. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buckner JC: Factors influencing survival
in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Das S and Marsden PA: Angiogenesis in
glioblastoma. N Engl J Med. 369:1561–1563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fine HA: The basis for current treatment
recommendations for malignant gliomas. J Neurooncol. 20:111–120.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wick W, Osswald M, Wick A and Winkler F:
Treatment of glioblastoma in adults. Ther Adv Neurol Disord.
11:17562864187904522018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen HS, Shabani S, Awad AJ, Kaushal M
and Doan N: Molecular markers of therapy-resistant glioblastoma and
potential strategy to combat resistance. Int J Mol Sci. 19(pii):
E17652018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Osswald M, Jung E, Sahm F, Solecki G,
Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M,
et al: Brain tumour cells interconnect to a functional and
resistant network. Nature. 528:93–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lefranc F, Le Rhun E, Kiss R and Weller M:
Glioblastoma quo vadis: Will migration and invasiveness reemerge as
therapeutic targets? Cancer Treat Rev. 68:145–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Onken J, Torka R, Korsing S, Radke J,
Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F and
Vajkoczy P: Inhibiting receptor tyrosine kinase AXL with small
molecule inhibitor BMS-777607 reduces glioblastoma growth,
migration and invasion in vitro and in vivo. Oncotarget.
9:9876–9889. 2016.
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J
and Califano A: An extensive microRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glioblastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun
H, Jiang Y, Zhang W, Liang A, Guo Y, et al: miR-139-5p suppresses
cancer cell migration and invasion through targeting ZEB1 and ZEB2
in GBM. Tumour Biol. 36:6741–6749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou X, Ren Y, Moore L, Mei M, You Y, Xu
P, Wang B, Wang G, Jia Z, Pu P, et al: Downregulation of miR-21
inhibits EGFR pathway and suppresses the growth of human
glioblastoma cells independent of PTEN status. Lab Invest.
90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W, Guo F, Wang P, Hong S and Zhang C:
miR-221/222 confers radioresistance in glioblastoma cells through
activating Akt independent of PTEN status. Curr Mol Med.
14:185–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiong X, Deng J, Zeng C, Jiang Y, Tang S
and Sun X: MicroRNA-141 is a tumor regulator and prognostic
biomarker in human glioblastoma. Oncol Lett. 14:4455–4460. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Avet-Loiseau H, Facon T, Grosbois B,
Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S and Bataille R;
Intergroupe Francophone du Myélome, : Oncogenesis of multiple
myeloma: 14q32 and 13q chromosomal abnormalities are not randomly
distributed, but correlate with natural history, immunological
features, and clinical presentation. Blood. 99:2185–2191. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang ZQ, Zhang MY, Deng ML, Weng NQ, Wang
HY and Wu SX: Low serum level of miR-485-3p predicts poor survival
in patients with glioblastoma. PLoS One. 12:e01849692017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tastet J, Decalonne L, Marouillat S, Malvy
J, Thépault RA, Toutain A, Paubel A, Tabagh R, Bénédetti H,
Laumonnier F, et al: Mutation screening of the ubiquitin ligase
gene RNF135 in French patients with autism. Psychiatr Genet.
25:263–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oshiumi H, Matsumoto M, Hatakeyama S and
Seya T: Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I
to promote interferon-beta induction during the early phase of
viral infection. J Biol Chem. 284:807–817. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin J, Zhao L and Li Z: The E3 ubiquitin
ligase RNF135 regulates the tumorigenesis activity of tongue cancer
SCC25 cells. Cancer Med. 5:3140–3146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tastet J, Decalonne L, Marouillat S, Malvy
J, Thépault RA, Toutain A, Paubel A, Tabagh R, Bénédetti H,
Laumonnier F, et al: Mutation screening of the ubiquitin ligase
gene RNF135 in French patients with autism. Psychiat Genet.
6:263–267. 2015. View Article : Google Scholar
|
|
24
|
Liu Y, Wang F, Liu Y, Yao Y, Lv X, Dong B,
Li J, Ren S, Yao Y and Xu Y: RNF135, RING finger protein, promotes
the proliferation of human glioblastoma cells in vivo and in vitro
via the ERK pathway. Sci Rep. 6:206422016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong D, Sheng Y, Ding S, Chen J, Tan X,
Zeng T, Qin D, Zhu L, Huang A and Tang H: LINC00052 regulates the
expression of NTRK3 by miR-128 and miR-485-3p to strengthen HCC
cells invasion and migration. Oncotarget. 7:47593–47608. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Batash R, Asna N, Schaffer P, Francis N
and Schaffer M: Glioblastoma multiforme, diagnosis and treatment;
recent literature review. Curr Med Chem. 24:3002–3009. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahir BK, Ozer H, Engelhard HH and Lakka
SS: MicroRNAs in glioblastoma pathogenesis and therapy: A
comprehensive review. Crit Rev Oncol Hematol. 120:22–33. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Henriksen M, Johnsen KB, Olesen P,
Pilgaard L and Duroux M: MicroRNA expression signatures and their
correlation with clinicopathological features in glioblastoma
multiforme. Neuromolecular Med. 16:565–577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun Y: Targeting E3 ubiquitin ligases for
cancer therapy. Cancer Biol Ther. 2:623–629. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu T, Wang H, Jiang M, Yan Y, Li W, Xu H,
Huang Q, Lu Y and Chen J: The E3 ubiquitin ligase CHIP/miR-92b/PTEN
regulatory network contributes to tumorigenesis of glioblastoma. Am
J Cancer Res. 7:289–300. 2017.PubMed/NCBI
|
|
34
|
Qi Z, Cai S, Cai J, Chen L, Yao Y, Chen L
and Mao Y: miR-491 regulates glioma cells proliferation by
targeting TRIM28 in vitro. BMC Neurol. 16:2482016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Douglas J, Cilliers D, Coleman K,
Tatton-Brown K, Barker K, Bernhard B, Burn J, Huson S, Josifova D,
Lacombe D, et al: Mutations in RNF135, a gene within the NF1
microdeletion region, cause phenotypic abnormalities including
overgrowth. Nat Genet. 39:963–965. 2007. View Article : Google Scholar : PubMed/NCBI
|
